Targeting cell surface β2-microglobulin by pentameric IgM antibodies

British Journal of Haematology

Volumn 154, Issue 1, 2011, Pages 111-121

  Cao, Yabing ^a,b   Lan, Yongsheng ^a   Qian, Jianfei ^a   Zheng, Yuhuan ^a   Hong, Sungyoul ^a   Li, Haiyan ^a   Wang, Michael ^a   Kwak, Larry W ^a   Lin, Dongyu ^b   Yang, Jing ^a   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Anti 2 mAbs; Haematological and solid tumours; IgM pentamer; Multiple myeloma; Tumour apoptosis

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BETA 2-MICROGLOBULIN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN M; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN-6; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958829840     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08714.x     Document Type: Article

References (31)

1. Adams, G.P. & Weiner, L.M. (2005) Monoclonal antibody therapy of cancer. Nature Biotechnology, 23, 1147-1157.
2. Anderson, K.C. (2004) Clinical update: novel targets in multiple myeloma. Seminars in Oncology, 31, 27-32, discussion 33.
3. Azuma, Y., Ishikawa, Y., Kawai, S., Tsunenari, T., Tsunoda, H., Igawa, T., Iida, S., Nanami, M., Suzuki, M., Irie, R.F., Tsuchiya, M. & Yamada-Okabe, H. (2007) Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. Clinical Cancer Research, 13, 2745-2750.
4. Bonner, J.A., Harari, P.M., Giralt, J., Azarnia, N., Shin, D.M., Cohen, R.B., Jones, C.U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M.S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E.K. & Ang, K.K. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 354, 567-578.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
6. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I. & Van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine, 351, 337-345.
7. Huang, Y.W. & Vitetta, E.S. (1993) A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Hybridoma, 12, 621-630.
8. Huang, W.C., Wu, D., Xie, Z., Zhau, H.E., Nomura, T., Zayzafoon, M., Pohl, J., Hsieh, C.L., Weitzmann, M.N., Farach-Carson, M.C. & Chung, L.W. (2006) beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Research, 66, 9108-9116.
9. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R. & Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335-2342.
10. Irie, R.F., Ollila, D.W., O'Day, S. & Morton, D.L. (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 53, 110-117.
11. Jain, R.K. & Baxter, L.T. (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Research, 48, 7022-7032.
12. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. & Thun, M.J. (2008) Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96.
13. Lankester, A.C., van Schijndel, G.M., Fromme, J., Cordell, J.L., van Lier, R.A. & van Noesel, C.J. (1994) Evidence for a direct physical interaction of membrane IgM, IgD, and IgG with the B29 gene product. Journal of Immunology, 152, 2157-2162.
14. Liu, Y.Y., Leboeuf, C., Shi, J.Y., Li, J.M., Wang, L., Shen, Y., Garcia, J.F., Shen, Z.X., Chen, Z., Janin, A., Chen, S.J. & Zhao, W.L. (2007) Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood, 110, 339-344.
15. Nomura, T., Huang, W.C., Seo, S., Zhau, H.E., Mimata, H. & Chung, L.W. (2007) Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. Journal of Urology, 178, 292-300.
16. Overman, M.J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J.E., Hagemeister, F.B., Kwak, L., Cabanillas, F., Rodriguez, M.A. & Fayad, L.E. (2008) The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Annals of Oncology, 19, 553-559.
17. Reichert, J.M. & Valge-Archer, V.E. (2007) Development trends for monoclonal antibody cancer therapeutics. Nature Reviews. Drug Discovery, 6, 349-356.
18. Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, Jr, C.E., Davidson, N.E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P.A., Swain, S.M., Pisansky, T.M., Fehrenbacher, L., Kutteh, L.A., Vogel, V.G., Visscher, D.W., Yothers, G., Jenkins, R.B., Brown, A.M., Dakhil, S.R., Mamounas, E.P., Lingle, W.L., Klein, P.M., Ingle, J.N. & Wolmark, N. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673-1684.
19. Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M. & Matsumoto, T. (2007) A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Research, 67, 1184-1192.
20. Shachar, I., Rabinovich, E., Kerem, A. & Bar-Nun, S. (1994) Thiol-reducing agents and calcium perturbants alter intracellular sorting of immunoglobulin M. Journal of Biological Chemistry, 269, 27344-27350.
21. Sonpavde, G. (2003) Bevacizumab in renal-cell cancer. New England Journal of Medicine, 349, 1674.
22. Spina, M., Simonelli, C. & Tirelli, U. (2007) Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Journal of Clinical Oncology, 25, e7.
23. Stein, R., Mattes, M.J., Cardillo, T.M., Hansen, H.J., Chang, C.H., Burton, J., Govindan, S. & Goldenberg, D.M. (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clinical Cancer Research, 13, 5556s-5563s.
24. Tai, Y.T., Catley, L.P., Mitsiades, C.S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., Richardson, P., Treon, S.P., Munshi, N.C. & Anderson, K.C. (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Research, 64, 2846-2852.
25. Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weller, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. & Anderson, K.C. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 1329-1337.
26. Tchoudakova, A., Hensel, F., Murillo, A., Eng, B., Foley, M., Smith, L., Schoenen, F., Hildebrand, A., Kelter, A.R., Ilag, L.L., Vollmers, H.P., Brandlein, S., McIninch, J., Chon, J., Lee, G. & Cacciuttolo, M. (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs, 1, 163-171.
27. Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. & Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 3712-3720.
28. de Weers, M., Tai, Y.T., van der Veer, M.S., Bakker, J.M., Vink, T., Jacobs, D.C., Oomen, L.A., Peipp, M., Valerius, T., Slootstra, J.W., Mutis, T., Bleeker, W.K., Anderson, K.C., Lokhorst, H.M., van de Winkel, J.G. & Parren, P.W. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology, 186, 1840-1848.
29. Yang, J., Qian, J., Wezeman, M., Wang, S., Lin, P., Wang, M., Yaccoby, S., Kwak, L.W., Barlogie, B. & Yi, Q. (2006) Targeting beta(2)-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10, 295-307.
30. Yang, J., Zhang, X., Wang, J., Qian, J., Zhang, L., Wang, M., Kwak, L.W. & Yi, Q. (2007) Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood, 110, 3028-3035.
31. Yang, J., Cao, Y., Hong, S., Li, H., Qian, J., Kwak, L.W. & Yi, Q. (2009) Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clinical Cancer Research, 15, 951-959.